These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19588574)

  • 1. Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET.
    Freesmeyer M; Schulz S; Knösel T; Settmacher U
    Nuklearmedizin; 2009; 48(3):N17-8. PubMed ID: 19588574
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
    Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
    Henze M; Schuhmacher J; Hipp P; Kowalski J; Becker DW; Doll J; Mäcke HR; Hofmann M; Debus J; Haberkorn U
    J Nucl Med; 2001 Jul; 42(7):1053-6. PubMed ID: 11438627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
    Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
    Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
    Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model.
    Chereau E; Durand L; Frati A; Prignon A; Talbot JN; Rouzier R
    Anticancer Res; 2013 Aug; 33(8):3015-9. PubMed ID: 23898054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
    Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
    Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
    Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
    Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma.
    Rabinowitz I; Telepak R; Lee FC
    Clin Nucl Med; 2002 Jul; 27(7):499-502. PubMed ID: 12072777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel use of somatostatin receptor scintigraphy in localization of focal congenital hyperinsulinism: promising but fallible.
    Dutta S; Venkataseshan S; Bal C; Rao KL; Gupta K; Bhattacharya A; Narang A
    J Pediatr Endocrinol Metab; 2009 Oct; 22(10):965-9. PubMed ID: 20020586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterisation of [67Ga] or [68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors.
    Stolz B; Smith-Jones PM; Albert R; Reist H; Mäcke H; Bruns C
    Horm Metab Res; 1994 Oct; 26(10):453-9. PubMed ID: 7851867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic and hepatobiliary cancers.
    Buck AK; Herrmann K; Eckel F; Beer AJ
    Methods Mol Biol; 2011; 727():243-64. PubMed ID: 21331938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
    Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
    Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
    [No Abstract]   [Full Text] [Related]  

  • 19. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
    Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
    J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.